A medical director for stem cell therapy clinics is a licensed physician who reviews treatment charts, signs off on regenerative protocols, and supervises injectors so the practice stays inside state medical board and FDA tissue rules. Stem cell, exosome, and amniotic-derived treatments draw more regulatory attention than Botox or filler because the FDA classifies the products themselves, not just the injection technique, which raises the compliance bar past what a typical medspa needs.
- A medical director for stem cell therapy clinics must sign off on chart review, good faith exams, and FDA product classification, not just supervise injections.
- US Medical Directors provides collaborating physician and chart review coverage for regenerative practices across many U.S. states.
- Stem cell products fall under FDA Section 361 or Section 351 rules, and that classification changes what physician sign-off you actually need.
- Skip in-house employed physicians if you’re a solo or small clinic — the fixed cost and CPOM restrictions rarely pencil out until you scale.
Why medical oversight matters for stem cell clinics
Regenerative medicine sits at the intersection of two regulatory systems: state medical board supervision rules (the same ones that govern medspas) and FDA rules for human cells, tissues, and cellular/tissue-based products, known as HCT/Ps under 21 CFR Part 1271. A medical director for exosome therapy clinics faces a nearly identical compliance stack, which is why regenerative practices increasingly hire the same type of physician oversight medspas use for injectables, just with tighter chart documentation.
Most states still classify stem cell and exosome injections as a medical procedure requiring physician-level supervision when performed by a nurse practitioner, PA, or non-physician provider. Corporate practice of medicine (CPOM) restrictions in states like California, Texas, and New York also limit who can own a regenerative clinic outright, which is exactly the structure a collaborating physician or medical director relationship is built to solve.
Get a medical director in place: the step-by-step
Confirm your FDA product classification first
Before you hire anyone, know whether your product is Section 361 (minimally manipulated, same-day, same-patient use) or Section 351 (more than minimally manipulated, treated as a drug requiring an Investigational New Drug application). This single distinction changes what level of physician sign-off you need before a procedure, not just for state licensing purposes.
- Pull the manufacturer's or lab's regulatory documentation for every product on your menu
- Check whether the product is autologous (patient's own cells) or allogeneic (donor-derived)
- Confirm same-day processing versus off-site manipulation
- Flag any product marketed with disease-treatment claims — a common FDA enforcement trigger
- Keep this classification on file; a state board or FDA inspector will ask for it
Map your state's supervision requirements
Supervision ratios, standing order rules, and collaborating physician requirements vary by state and by provider type (RN, NP, PA). A clinic operating in more than one state needs a separate compliance map for each location.
- List every state where you treat patients, including telehealth follow-up
- Identify whether your state requires in-person or remote physician availability
- Check NP independent-practice status — several states no longer require a collaborating physician for NPs at all
- Confirm whether your state treats stem cell injections differently from standard aesthetic injectables
- Note renewal timelines for any existing collaborating physician agreement
Vet a collaborating physician who understands regenerative medicine
A general aesthetics-focused collaborating physician may never have reviewed an HCT/P chart. Ask direct questions before signing anything.
- Ask for specific experience with stem cell, exosome, or amniotic-tissue protocols, not just Botox and filler
- Confirm they understand Section 361 versus Section 351 distinctions
- Verify active license status and any board actions in the state where you operate
- Ask how many charts they can realistically review per month
- Get availability commitments in writing, including backup coverage
This is also where a service like US Medical Directors enters as the faster path once you've mapped your own state requirements — the manual route above still applies even if you outsource the search.
Build a chart review workflow for every procedure
Chart review is the paper trail that proves supervision actually happened, and it's the first thing a state board pulls during an inspection.
- Document patient history, product lot number, and injection site for every visit
- Log physician sign-off with a timestamp, not just a signature at month-end
- Flag any adverse reaction and the physician's response within 24-48 hours
- Store records in a format that survives a staffing change or clinic sale
- Review the chart review services for medspas options if you're building this from scratch
Schedule good faith exams before the first injection
A good faith exam (GFE) is the in-person or documented evaluation that confirms a patient is a candidate for treatment. Most states require one before any injectable procedure, and stem cell clinics are no exception.
- Book the GFE before the first stem cell or exosome session, not after
- Re-evaluate at intervals your state requires for repeat patients
- Document contraindications specific to regenerative products (autoimmune conditions, active infection, prior allergic reaction)
- Keep GFE records tied to the same chart as ongoing treatment notes
- Check the good faith exams for medspas guide for the documentation standard most boards expect
Draft standing orders specific to regenerative protocols
Generic standing orders written for Botox and filler rarely cover stem cell dosing, product handling, or injection depth for regenerative treatments. Write protocols specific to what you actually inject.
- Include product-specific dosing and site protocols
- Cover storage and handling chain-of-custody for cellular products
- Define escalation steps for adverse reactions unique to regenerative injections
- Update standing orders whenever you add a new product line
Budget for oversight realistically
Medical director and collaborating physician arrangements cost more for regenerative clinics than for standard medspas because the chart review burden and liability exposure are higher. Build that into your operating budget before you sign a lease or launch a service.
- Compare per-provider versus per-clinic pricing models
- Factor in GFE volume based on patient count, not a flat estimate
- Ask whether multi-location coverage is priced per site or bundled
- Confirm what happens to pricing if you add products classified under Section 351
Comparison: oversight options for stem cell clinics
| Option | Best for | Key limitation |
|---|---|---|
| Independent contracted physician | Solo or single-location clinics | Single point of failure if unavailable |
| Medical director service network | Multi-location or scaling regenerative practices | Requires vetting for regenerative-specific experience |
| In-house employed physician | Large, well-capitalized practices | Highest fixed cost; CPOM restrictions in several states |
| Telehealth-only collaborating physician | Chart review and GFE support only | Doesn't cover in-person emergency response |
Verdict: for most independent stem cell and exosome clinics scaling past one location, a medical director service built around regenerative-specific chart review beats an in-house hire on cost and beats a solo contracted physician on redundancy.
Get medical director coverage in place
Compliance support built for aesthetic and regenerative medicine practices.
Common mistakes stem cell clinics make
- Treating stem cell supervision like Botox supervision. The FDA product classification adds a compliance layer that standard aesthetic supervision agreements don't cover.
- Skipping the good faith exam for repeat patients. Boards expect re-evaluation at intervals, not a single sign-off at intake.
- Hiring a collaborating physician with zero regenerative medicine background. They'll sign charts but won't catch product-specific red flags.
- Ignoring CPOM rules when structuring ownership. Several states restrict non-physician ownership of a practice performing these procedures, which changes your entire business structure.
- Underbudgeting for chart review volume. Regenerative clinics generate denser documentation per visit than a standard filler appointment, and pricing should reflect that.
FAQ
Does a stem cell therapy clinic need a medical director in 2026?
Most states require physician-level supervision for stem cell and exosome injections performed by a nurse practitioner, PA, or nurse injector in 2026. Check your specific state board rules, since NP independent-practice states may not require a collaborating physician for every provider type.
What’s the difference between FDA Section 361 and Section 351 products?
Section 361 covers minimally manipulated, same-day, same-patient tissue products, while Section 351 treats more heavily processed or donor-derived products as drugs requiring an Investigational New Drug application. Your product’s classification determines the level of physician oversight and documentation required.
How is medical director oversight different for stem cell clinics versus medspas?
Stem cell clinics carry an added FDA tissue-product compliance layer on top of the same state supervision rules medspas follow. Chart review and good faith exam documentation both need to be more detailed to reflect product classification and handling.
Can a nurse practitioner own a stem cell clinic without a physician?
It depends on the state’s corporate practice of medicine rules. Some states restrict non-physician ownership entirely, while others allow it with a collaborating physician agreement in place.
How often do good faith exams need to happen for stem cell patients?
Frequency depends on state requirements, but most boards expect a GFE before the first treatment and re-evaluation at set intervals for repeat patients. Check your state medical board’s specific interval requirement.
Is a telehealth collaborating physician enough for a stem cell clinic?
Telehealth coverage works for chart review and documentation but usually doesn’t satisfy in-person supervision or emergency response requirements many states impose on regenerative procedures. Pair it with a physician who can respond to adverse events in person or confirm your state doesn’t require that.
What does a medical director actually review for a stem cell clinic?
A medical director reviews patient charts, good faith exam documentation, product classification records, and standing order compliance for every regenerative procedure performed. That review creates the paper trail a state board or FDA inspector expects during an audit.
Do multi-location stem cell clinics need separate physicians per state?
Yes, in most cases — collaborating physician agreements and supervision ratios are state-specific, so a clinic operating in multiple states needs coverage mapped to each state’s individual rules.
One last thing
The detail most stem cell clinics miss isn't a supervision ratio or a licensing fee — it's the FDA's 361 versus 351 classification sitting quietly underneath their state compliance paperwork. A clinic can have a perfect collaborating physician agreement on file and still be out of compliance if the product itself is misclassified. Check the classification before the marketing copy goes up, not after a board inquiry.
Related guides
- How to hire a medical director for your aesthetics practice
- Medical director for peptide therapy clinics
